Get started
Author

Yi June Kim

Observed name: Yi J. Kim
ORCID: 0000-0002-8364-7971
Observed ORCID: 0000-0002-8364-7971
OpenAlex ID: A5036637982
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1 -Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al. · Blood Cancer Discovery · 137
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
2024 · Guillermo Montalban-Bravo, Natthakan Thongon, et al. · Cell Reports Medicine · 14
Emerging technologies of single-cell multi-omics
2025 · Yi June Kim, Koichi Takahashi · Haematologica · 13
PDF
Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes
2025 · Juan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, et al. · Nature Communications · 10
PDF
Mutant Natural Killer Cell Dysfunction Enables the Immune Escape of Premalignant MDS Cell Clones
2023 · Irene Ganan-Gomez, Bijender Kumar, et al. · Blood · 2
PDF
Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia
2025 · Yi June Kim, Ken Furudate, et al. · Blood · 1
PDF
Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms
2023 · Yi June Kim, Zongrui Li, et al. · Blood · 1
PDF
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2025 · Curtis A. Lachowiez, Sanam Loghavi, et al.
PDF
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2025 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2025 · Curtis A. Lachowiez, Sanam Loghavi, et al.
PDF
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2025 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
2024 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
2024 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
2024 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Abstract 3400: Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms
2024 · Yi June Kim, Zongrui Li, et al. · Cancer Research
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
PDF
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
2023 · Curtis A. Lachowiez, Sanam Loghavi, et al.
PDF
Immune microenvironment dysfunctions enable malignification at the onset of myelodysplastic syndromes
2022 · Irene Ganan-Gomez, Feiyang Ma, et al. · Leading Edge of Cancer Research Symposium
PDF
Works count: 22
Citation count: 178
H-index: 4
I10-index: 4
Year
Topic
Type